Company: OSRH
Filing Date: 2025-06-23
Form Type: 424B3
Source: 0001213900-25-056351
Chunk: 106

Company: OSR Holdings, Inc.
Filing Date: 2025-06-23
Form: 424B3
Chunk 106
---
izzera Italiana in Lugano, Switzerland. Dr. Barberis
earned a PhD in Molecular Biology and Biochemistry from the University of Zürich (1988). Dr. Barberis is well qualified to
serve as a Director because of his extensive management and leadership experience in the biotech industry, startup companies, and in
the private and public scientific research sectors.

<div align='center'>64</div>

Dr. Seng Chin Mah became a Director
of the Company as of the Closing of the Business Combination. Dr. Mah has been Chairman of the Board of BioVersys AG since
2009. He was previously Chief Executive Officer of the Canyon Pharmaceuticals Group AG (2009-2021) and has over 30 years’
experience in the pharma and biotech industry. Prior to Canyon Pharmaceuticals, he was Head of Development of the Integration Office
during the integration of Chiron into Novartis (2005-2008) and held other positions at Novartis, including Global Head of Clinical Safety
and Epidemiology (2001-2005); Head of Drug Regulatory Affairs Europe (1997-2001); and oversight responsibility for Clinical Quality Assurance
(2001-2005). Dr. Mah was also a member of the Novartis Corporate Executive Group (2001-2005) and a member of the Board of Directors
for Novartis Europharm Ltd. (1997-2005). During his tenure with Novartis and Ciba (1990-2008), he drove key drug development and regulatory
programs, and led major business results including numerous global registrations of major products. He has held several research and
academia positions (Ciba-Geigy Ltd., 1987-1988; National University of Singapore, 1989-1990). Dr. Mah was awarded
The Frost & Sullivan 2011 Product Differentiation Excellence Award in Parenteral Anticoagulants, which recognized Canyon Pharmaceuticals
Group AG for the development and launch of Iprivask (desirudin for injection). Dr. Mah earned a BS in Pharmacology
from University of London (1984) and a PhD in Biochemistry from University of Basel (1987). Dr. Mah is well qualified to serve
as a Director because of his extensive knowledge and experience in strategic decision-making, late-stage clinical development and
regulatory experience within the Pharma and Biotech industry.

Jin Whan Parkhas been a Director
of the Company since February